NEW YORK, March 9 /PRNewswire/ -- Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that two of its oncology thought leaders will be presenting their insights on market access and oncology target populations at upcoming oncology conferences.
Lee Blansett, Senior Vice President, will address how new rules and policy changes will affect pricing of oncology products and whether the new regulations will stifle innovation. Kevin Norell, Senior Vice President, will address how the expanding role of biomarkers could affect key business development decisions, particularly whether manufacturers can afford to pursue smaller subsegments of patients based on potential market forecasts.
Mr. Blansett will be a featured speaker at the 21st Annual Cancer Progress Conference, the hallmark conference for pharmaceutical and biotechnology executives, which will be held March 16-17, 2010, at the Hilton New York in New York City. Mr. Blansett's presentation is titled "Market Access Under Healthcare Reform." This presentation is recommended for senior executives concerned with market access and pricing for in-line and pipeline products targeting cancer and other severe diseases.
Mr. Blansett leads Kantar Health's U.S. market access practice and is deeply involved with the company's global market access practice. His engagements address commercial and public reimbursement, market access, government policy, managed care, and provider economics. His provider and plan experience includes current work with oncology medical groups and prior work with Stanford Medical Center, Kaiser Foundation Health Plans / The Permanente Medical Group, and APM.
Mr. Norell will be a featured speaker at eyeforpharma's Oncology USA Summit, which will be held March 23-24, 2010, at the Park Plaza Hotel in Boston. Mr. Norell will present "Insights into the New Reality: Do smaller target populations provide ROI?" on March 24 as part of the session "The Role of Biomarkers in Commercialization."
Mr. Norell leads Kantar Health's Advanced Applications and Modeling team, which provides new product forecasting and investment analysis, development of pro forma financials, and analysis of acquisitions and divestitures. He is a highly regarded modeler and an expert in the field of oncology forecasting. Before joining Kantar Health, Mr. Norell was an Operations Manager and Financial Analyst, analyzing financial operations and valuations of acquisition candidates.
For the sixth consecutive year Kantar Health is a major sponsor of the Cancer Progress Conference.
Kantar Health is a Global Sponsor for Oncology USA Summit.
About Kantar Health
Kantar Health is a leading healthcare-focused global consultancy, specializing in portfolio optimization, market access, safety and outcomes, and brand and customer insights Formed by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare and Ziment, it is the next-generation decision support partner to the pharmaceutical and biotech industries, delivering evidence-based guidance to support clients' global and local success.
With 40+ offices throughout the Americas, Europe, Asia-Pacific, the Middle East and Africa, Kantar Health provides the broadest global footprint, coupled with the strongest local knowledge to help drive clients' maximum performance in every geography. Market-leading solutions ensure optimal decisions and actions across the brand life cycle, from assessing opportunities and sizing markets…to developing products and building access strategies…to positioning brands and creating messaging…to managing stakeholder relationships and monitoring treatment outcomes.
SOURCE Kantar HealthBack to top
|SOURCE Kantar Health|
Copyright©2010 PR Newswire.
All rights reserved